Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab in Newly Diagnosed Adult ALS Patients
NCT06453668Phase 1Terminated
- Sponsor
- ITB-MED
- Start
- Apr 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of siplizumab in amyotrophic lateral sclerosis (ALS), sponsored by ITB-MED. Primary endpoint: Evaluation of the safety of TCD601 at 12 months. Started Apr 2024; status: terminated.
02
Drugs
siplizumab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06453668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453668.